Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-W062835 |
Brand: | MCE |
CAS: | 234772-64-6 |
MDL | MFCD20039929 |
---|---|
Molecular Weight | 443.54 |
Molecular Formula | C26H29N5O2 |
SMILES | OC1CCN(CCC2=CC=C(N3C=C(C4=CC=CC(OC)=C4)C5=C(N)N=CN=C53)C=C2)CC1 |
CGP77675 is an orally active and potent inhibitor of Src family kinases. CGP77675 inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src ( IC 50 s of 5-20 and 40 nM, respectively), and also inhibits Src , EGFR , KDR, v-Abl, and Lck with IC 50 s of 5-20, 40, 20, 150, 1000, 310, and 290 nM, respectively. Anticancer activity [1] .
IC50: 0.02 μM (Src), 0.15 μM (EGFR), 1.0 μM (KDR), 0.31 μM (v-Abl), 0.29 μM (Lck) [1]
CGP77675 dose dependently inhibits phosphorylation of poly-Glu-Tyr with an IC
50
value of 5.5 nM, and of the optimal Src substrate (OSS) peptide with an IC
50
value of 16.7 nM. These IC
50
values are similar to the value obtained with chicken Src (20 nM)
[1]
.
CGP77675 inhibits the parathyroid hormone-induced bone resorption in rat fetal long bone cultures with an IC
50
of 0.8 μM
[1]
.
CGP77675 (0.04-10 μM; 2 hours) potently inhibits tyrosine phosphorylation of the Src substrates Fak and paxillin, but has much less effect on Src (IC
50
values 0.2, 0.5, and 5.7μM) in IC8.1 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
Cell Line: | MC3T3-E1 cells |
Concentration: | 0.2, 1, and 5 μM |
Incubation Time: | 3 days |
Result: | Did not influence cell viability for up to 3 days of treatment. |
Western Blot Analysis [1]
Cell Line: | Src-overexpressing IC8.1 cells |
Concentration: | 0.04, 0.2, 1, 5, and 10 μM |
Incubation Time: | 2 hours |
Result: | Dose dependently inhibited phosphorylation of Fak and paxillin, but not of Src. |
CGP77675 (1, 5, and 25 mg/kg; injected s.c.; twice a day) inhibits IL-1β-induced hypercalcemia in Mice
[1]
.
CGP77675 (10 and 50 mg/kg; administered orally; twice a day for 6 weeks) partially prevents bone loss and rescues bone microarchitectural features in young ovx rats
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Male mice (Tif:MAGf; Novartis Animal Farm) of 25-30 g body [1] |
Dosage: | 1, 5, and 25 mg/kg |
Administration: | Injected s.c.; twice a day |
Result: | Prevented IL-1β-induced hypercalcemia in mice without affecting serum amyloid protein levels. |
Animal Model: | Eight-week-old (175-209 g) female rats of the Sprague-Dawley-derived strain Tif:RAlf [1] |
Dosage: | 10 and 50 mg/kg |
Administration: | Administered orally; twice a day for 6 weeks |
Result: | Partly prevented bone loss. |
Solid
Room temperature in continental US; may vary elsewhere.
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
DMSO : 26.0 mg/mL ( 58.62 mM ; Need ultrasonic and warming)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.2546 mL | 11.2729 mL | 22.5459 mL |
5 mM | 0.4509 mL | 2.2546 mL | 4.5092 mL |
10 mM | 0.2255 mL | 1.1273 mL | 2.2546 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.